A phase 1B clinical trial to evaluate the safety and immunogenicity of recombinant adenoviral serotype 35 (rAd35) and serotype 5 (rAd5) HIV-1 vaccines when given in heterologous prime-boost regimens or as a boost to a recombinant DNA vaccine in healthy, HIV-1-uninfected adult participants with pre-existing immunity to adenovirus serotype 5 infection.

Trial Profile

A phase 1B clinical trial to evaluate the safety and immunogenicity of recombinant adenoviral serotype 35 (rAd35) and serotype 5 (rAd5) HIV-1 vaccines when given in heterologous prime-boost regimens or as a boost to a recombinant DNA vaccine in healthy, HIV-1-uninfected adult participants with pre-existing immunity to adenovirus serotype 5 infection.

Completed
Phase of Trial: Phase I

Latest Information Update: 13 Feb 2015

At a glance

  • Drugs VRC-HIVADV027-00-VP (Primary) ; VRC-HIVADV038-00-VP (Primary) ; VRC-HIVDNA044-00-VP (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 07 May 2013 Status changed from active, no longer recruiting to completed as reported by clinicaltrials.gov.
    • 29 Mar 2012 Status changed from completed to active, no longer recruiting as reported by clinicaltrials.gov.
    • 01 Sep 2009 Status changed from active, no longer recruiting to completed as reported by clinicaltrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top